Home › Free Stock Grades › PLX
Protalix BioTherapeutics, Inc. (PLX) Stock Grade
PLX · Healthcare
B-
Market Cap
$216.7M
P/E Ratio
5.9
Revenue Growth (YoY)
-1.2%
Net Margin
-12.5%
Return on Equity
—
Dividend Yield
None
About Protalix BioTherapeutics, Inc.'s fundamentals
Protalix BioTherapeutics is a biotechnology company with a market capitalization of $216.7 million that is currently unprofitable, reporting a net loss in its latest annual statement with a net margin of -12.5%. The company's revenue declined 1.2% year-over-year, indicating a contraction in sales, and it does not pay a dividend. With a P/E ratio of 5.9, the valuation metric is based on historical earnings rather than current profitability, reflecting the company's loss-making status.